ClinicalTrials.gg
CompletedNCT04762498FORWARD OLUpdated May 19, 2026Results posted

A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

A Phase 4 interventional study of Pegloticase and Methotrexate (MTX) in Uncontrolled Gout and Chronic Gout, sponsored by Amgen. Completed at 12 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
8th of 14
54 · median 93
Started
2021
with 1 other
Phase 4
7 of 14
none open now
Registered
11th of 14
by date
Lead sponsor
8 of 14
Amgen

Among the 14 studies testing pegloticase in Gout, this one is the 8th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 4, and was the 11th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

This trial is to assess efficacy, safety, blood levels and bodily effects of up to 2 dose levels of intravenous (IV) pegloticase (KRYSTEXXA) infusions at every 4 week intervals (Q4 Weeks) for up to 6 months (Day 1 to 24 weeks with an optional 24 - 48 weeks treatment duration) when given in combination with weekly oral doses of methotrexate (MTX). The goal is to identify an appropriate dose to be administered every 4 weeks to be used for future clinical trials for patients with chronic gout that does not adequately respond to conventional therapy.

Read the detailed description

The primary objective is to choose a dose for further investigation by assessing the effect of up to 2 dose levels of pegloticase administered IV Q4 weeks, co-administered with weekly doses of oral MTX, as measured by the sustained normalization of serum uric acid (sUA) to \< 6 mg/dL for at least 80% of the time during Month 6 and the duration of sUA to \< 6 mg/dL over 24 week treatment period in adult participants with chronic gout refractory to conventional therapy.

Acquired from Horizon in 2024.

03

Conditions studied

  • Uncontrolled Gout
  • Chronic Gout

Browse trials for

Keywords

  • Gout
  • KRYSTEXXA
  • Pegloticase
  • Methotrexate
  • Uncontrolled gout
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give .
  2. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.
  3. Adult men or women ≥18 and \<80 years of age.
  4. Uncontrolled gout, defined as meeting the following criteria:

    • Hyperuricemia during the screening period defined as sUA ≥6 mg/dL, and;
    • Failure to maintain normalization of sUA with xanthine oxidase inhibitors at the maximum medically appropriate dose, or with a to xanthine oxidase inhibitor therapy based on medical record review or subject interview, and;
    • Symptoms of gout including at least 1 of the following:

      • Presence of at least one tophus
      • Recurrent flares defined as 2 or more flares in the past 12 months prior to screening
      • Presence of chronic gouty arthritis as evidenced by either clinical signs consistent with chronic synovitis on clinical examination or the presence of typical gouty erosion(s) on hand and/or foot X-rays
  5. Willing to discontinue any oral urate lowering therapy for at least 7 days prior to MTX dosing at Week -4 and remain off while receiving pegloticase treatments.
  6. Women of (including those with an onset of menopause \<2 years prior to screening, non-therapy-induced amenorrhea for \<12 months prior to screening, or not surgically sterile [absence of ovaries and/or uterus]) must have negative serum/urine pregnancy tests during Screening and Week -4; subjects must agree to use 2 reliable forms of during the trial, one of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started ≥1 full cycle prior to Week -4 (start of MTX) and continue for 4 weeks/30 days after the last dose of pegloticase, or at least one ovulatory cycle after the last dose of MTX (whichever is the longest duration after the last dose of pegloticase or MTX). Highly effective contraceptive methods (with a failure rate \<1% per year), when used consistently and correctly, include implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or vasectomized partner.
  7. Men who are not vasectomized must agree to use appropriate contraception so as to not impregnate a female partner of during the trial, beginning with the initiation of MTX at Week -4 and continuing and for at least 3 months after the last dose of MTX.
  8. Able to tolerate MTX 15 mg orally for 4 weeks (Week -4 through Day 1) prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Weight >160 kg (352 pounds) at Screening.
  2. Any serious acute bacterial infection, unless treated and completely resolved with antibiotics at least 2 weeks prior to the Day 1 Visit.
  3. Severe chronic or recurrent bacterial infections, such as recurrent pneumonia or chronic bronchiectasis.
  4. Current or chronic treatment with systemic agents such as MTX, azathioprine, or mycophenolate mofetil; prednisone ≥10 mg/day or equivalent dose of other on a chronic basis (3 months or longer) would also meet exclusion criteria.
  5. History of any transplant surgery requiring maintenance immunosuppressive therapy.
  6. Known history of virus surface antigen positivity or hepatitis B DNA positivity.
  7. Known history of virus RNA positivity, unless treated and viral load is negative.
  8. Known history of (HIV) positivity.
  9. Glucose-6-phosphate dehydrogenase deficiency (tested at the Screening Visit centrally or locally).
  10. Chronic renal impairment defined as estimated (eGFR) \<40 mL/min/1.73 m\^2 or currently on dialysis.
  11. Non-compensated congestive heart failure or hospitalization for congestive heart failure within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled blood pressure (>160/100 mmHg) prior to enrollment at Day 1.
  12. Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female partner, or not on an effective form of , as determined by the Investigator.
  13. Prior treatment with pegloticase, another recombinant uricase (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug.
  14. Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product.
  15. to MTX treatment or MTX treatment considered inappropriate.
  16. Known intolerance to MTX.
  17. Receipt of an drug within 4 weeks or 5 half-lives, whichever is longer, prior to MTX administration at Week -4 or plans to take an investigational drug during the trial.
  18. Liver transaminase levels ( or ALT) > 1.25 X (ULN) or albumin \< the lower limit of normal (LLN) at the Screening Visit.
  19. Chronic liver disease.
  20. White blood cell count \<4000/µl, hematocrit \<32 percent, or count \<75,000/µl.
  21. Currently receiving systemic or radiologic treatment for ongoing cancer, excluding non-melanoma skin cancer.
  22. History of within 5 years other than non-melanoma skin cancer or in situ carcinoma of cervix.
  23. Diagnosis of osteomyelitis.
  24. Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
  25. Unsuitable candidate for the trial, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the trial.
  26. Alcohol use in excess of 3 alcoholic beverages per week.
  27. A known intolerance to all protocol standard gout flare prophylaxis regimens (i.e., subject must be able to tolerate at least one: colchicine and/or non-steroidal anti-inflammatory drugs and/or low dose prednisone ≤10 mg/day).
  28. Current pulmonary fibrosis, bronchiectasis or interstitial pneumonitis. If deemed necessary by the Investigator, a chest X-ray may be performed during Screening.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Pegloticase 16mg cohort

    16 mg IV dose of pegloticase q4 weeks with 15 mg methotrexate (MTX) weekly

    Biological: Pegloticase · Drug: Methotrexate (MTX)

  • Experimental
    Pegloticase 24/32mg cohort

    24 to 32 mg IV dose of pegloticase q4 weeks with 15 mg MTX weekly

    Biological: Pegloticase · Drug: Methotrexate (MTX)

Interventions

  • BiologicalPegloticase

    IV dose of pegloticase q4 weeks co-administered with weekly oral methotrexate

  • 15 mg oral dose methotrexate administered weekly

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Were Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6

    Responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 6. Participants meeting the sUA discontinuation criteria (pre-infusion sUA \>6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 1 Visit) were counted as non-responders.

    Time frame: Month 6 (Weeks 20, 21, 22, 23, and 24)

  2. Time to First sUA ≥6 mg/dL After First Achieving sUA <6 mg/dL, From the First Pegloticase Infusion Until Week 24

    The number of participants who had pre-Infusion sUA ≥ 6 mg/dL post-day 1 pegloticase infusion were included in this analysis. The date of the first pre-infusion sUA ≥ 6 mg/dL was the event date. Participants who did not have the event were censored at the date of the last collected pre-infusion sample with non-missing sUA result. Participants who never achieved sUA \< 6 mg/dL were excluded from the analysis.

    Time frame: Day 1 to Week 24

Secondary outcomes

  1. Maximum Concentration (Cmax) of Pegloticase

    Noncompartmental Pharmacokinetic (PK) parameters of pegloticase were estimated using concentration data after the first dose (including Week 4 predose concentration data) using Phoenix WinNonlin® software. The linear/log trapezoidal rule was used in conjunction with the appropriate noncompartmental model, with input values for dose level, dosing time, serum concentration, and corresponding real-time values, based on drug dosing times whenever possible. Below limit of quantification (BLQ) values prior to the first quantifiable concentration were set to 0; BLQ values at all other time points were set to half the lower limit of quantification (LLOQ) (0.025 µg/mL).

    Time frame: Post infusion on Day 1, at Weeks 1, 2, 3 and pre-dose at Week 4

  2. Area Under the Concentration- Time Curve From Time 0 to Week 4 Predose of Pegloticase

    Noncompartmental PK parameters of pegloticase were estimated using concentration data after the first dose (including Week 4 predose concentration data) using Phoenix WinNonlin® software. The linear/log trapezoidal rule was used in conjunction with the appropriate noncompartmental model, with input values for dose level, dosing time, serum concentration, and corresponding real-time values, based on drug dosing times whenever possible. BLQ values prior to the first quantifiable concentration were set to 0; BLQ values at all other time points were set to half LLOQ (0.025 µg/mL).

    Time frame: Post infusion on Day 1, at Weeks 1, 2, 3 and pre-dose at Week 4

  3. Trough Serum Concentration (Ctrough) of Pegloticase at Week 24 Pre-dose

    Blood samples were collected for measurement of serum concentrations of pegloticase. The median concentration of pegloticase taken at Week 24 pre-dose was reported as the Ctrough concentration at Week 24.

    Time frame: Week 24 Pre-dose

  4. Percentage of Participants With Pre-infusion sUA <6 mg/dL at Each Scheduled Visit

    The percentage of participants with pre-infusion sUA \<6 mg/dL at each scheduled infusion visit, regardless of treatment status, was presented.

    Time frame: Pre-infusion on Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 and 44

  5. Area Under the sUA Concentration vs Time Curve From Day 1 to Week 24 and Day 1 to Week 48

    The AUC from Day 1 to Week 24 and from Day 1 to Week 48 was calculated as time-adjusted AUC derived using the trapezoidal rule divided by the number of total days in the given period. The AUC from Day 1 to Week 48 was only calculated for participants who continued in the optional treatment period from Week 24 to Week 48.

    Time frame: Day 1 to Week 24 and Day 1 to Week 48

  6. Percentage of Time Participants Sustained sUA < 6 mg/dL From Day 1 to Week 24 or Day 1 to Week 48

    The percentage of time that participants sustained sUA \< 6 mg/dL was derived using linear interpolation across all observed data points between Day 1 and the end of each analysis period. The percentage of time during a given period is the time that sUA \< 6 mg/dL divided by the total time from the first to the last scheduled visit in the given period.

    Time frame: Day 1 to Week 24 and Day 1 to Week 48

  7. Percentage of Participants With Anti-uricase Antibodies at Each Scheduled Visit

    Pegloticase immunogenicity was assessed by incidence of anti-poly (Ethylene Glycol) (PEG) and anti-uricase immunoglobulin G (IgG) antibodies. The percentage of participants who were treatment-emergent anti-drug antibody (ADA) positive is presented below. Participants were considered treatment-emergent ADA positive if they were ADA negative at the data collection timepoint of Day 1 (Baseline) and ADA positive at one of the specified post-dose timepoints.

    Time frame: Day 1 (Baseline) and Weeks 2, 4, 8, 16, 24, 36 and 48

  8. Percentage of Participants With Anti-PEG Antibodies at Each Scheduled Visit

    Pegloticase immunogenicity was assessed by incidence of anti-PEG and anti-uricase IgG antibodies. The percentage of participants who were treatment-emergent ADA positive is presented below. Participants were considered treatment-emergent ADA positive if they were ADA negative at the data collection timepoint of Day 1 (Baseline) and ADA positive at one of the specified post-dose timepoints.

    Time frame: Day 1 (Baseline) and Weeks 2, 4, 8, 16, 24, 36 and 48

07

Results

Posted May 19, 2026

Participant flow

A total of 54 participants were enrolled into this trial in the United States between March 2021 and December 2023.

MTX Run-in
Participant flow — MTX Run-in
MilestoneMTX Run-inPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Started5400
Completed5100
Not completed300
Withdrew: Screen failure300
Pegloticase + MTX Treatment Period
Participant flow — Pegloticase + MTX Treatment Period
MilestoneMTX Run-inPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Started02526
Completed02224
Not completed032
Withdrew: Death010
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by subject012
Optional Extension Period
Participant flow — Optional Extension Period
MilestoneMTX Run-inPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Started01719
Completed01615
Not completed014
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by subject004

Outcome measures

SecondaryMaximum Concentration (Cmax) of Pegloticase

Noncompartmental Pharmacokinetic (PK) parameters of pegloticase were estimated using concentration data after the first dose (including Week 4 predose concentration data) using Phoenix WinNonlin® software. The linear/log trapezoidal rule was used in conjunction with the appropriate noncompartmental model, with input values for dose level, dosing time, serum concentration, and corresponding real-time values, based on drug dosing times whenever possible. Below limit of quantification (BLQ) values prior to the first quantifiable concentration were set to 0; BLQ values at all other time points were set to half the lower limit of quantification (LLOQ) (0.025 µg/mL).

Time frame:
Post infusion on Day 1, at Weeks 1, 2, 3 and pre-dose at Week 4
Reported as:
Geometric mean · μg/mL
Maximum Concentration (Cmax) of Pegloticase
μg/mLPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Maximum Concentration (Cmax) of Pegloticase6.09 ± 3311 ± 33
SecondaryArea Under the Concentration- Time Curve From Time 0 to Week 4 Predose of Pegloticase

Noncompartmental PK parameters of pegloticase were estimated using concentration data after the first dose (including Week 4 predose concentration data) using Phoenix WinNonlin® software. The linear/log trapezoidal rule was used in conjunction with the appropriate noncompartmental model, with input values for dose level, dosing time, serum concentration, and corresponding real-time values, based on drug dosing times whenever possible. BLQ values prior to the first quantifiable concentration were set to 0; BLQ values at all other time points were set to half LLOQ (0.025 µg/mL).

Time frame:
Post infusion on Day 1, at Weeks 1, 2, 3 and pre-dose at Week 4
Reported as:
Geometric mean · hr*μg/mL
Area Under the Concentration- Time Curve From Time 0 to Week 4 Predose of Pegloticase
hr*μg/mLPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Area Under the Concentration- Time Curve From Time 0 to Week 4 Predose of Pegloticase1670 ± 343120 ± 25
SecondaryTrough Serum Concentration (Ctrough) of Pegloticase at Week 24 Pre-dose

Blood samples were collected for measurement of serum concentrations of pegloticase. The median concentration of pegloticase taken at Week 24 pre-dose was reported as the Ctrough concentration at Week 24.

Time frame:
Week 24 Pre-dose
Reported as:
Median · μg/mL
Trough Serum Concentration (Ctrough) of Pegloticase at Week 24 Pre-dose
μg/mLPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Trough Serum Concentration (Ctrough) of Pegloticase at Week 24 Pre-dose1.33 (0.932 to 2.39)2.76 (2.10 to 3.11)
SecondaryPercentage of Participants With Pre-infusion sUA <6 mg/dL at Each Scheduled Visit

The percentage of participants with pre-infusion sUA \<6 mg/dL at each scheduled infusion visit, regardless of treatment status, was presented.

Time frame:
Pre-infusion on Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · percentage of participants
Percentage of Participants With Pre-infusion sUA <6 mg/dL at Each Scheduled Visit
percentage of participantsPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Day 1 - Pre-infusion0 (0.0 to 13.7)3.8 (0.1 to 19.6)
Week 4 - Pre-infusion83.3 (62.6 to 95.3)84.6 (65.1 to 95.6)
Week 8 - Pre-infusion78.3 (56.3 to 92.5)84.6 (65.1 to 95.6)
Week 12 - Pre-infusion86.4 (65.1 to 97.1)87.5 (67.6 to 97.3)
Week 16 - Pre-infusion85.7 (63.7 to 97.0)83.3 (62.6 to 95.3)
Week 20 - Pre-infusion90.5 (69.6 to 98.8)82.6 (61.2 to 95.0)
Week 24 - Pre-infusion85.7 (63.7 to 97.0)82.6 (61.2 to 95.0)
Week 28 - Pre-infusion100 (80.5 to 100.0)88.9 (65.3 to 98.6)
Week 32 - Pre-infusion94.1 (71.3 to 99.9)88.9 (65.3 to 98.6)
Week 36 - Pre-infusion88.2 (63.6 to 98.5)88.2 (63.6 to 98.5)
Week 40 - Pre-infusion100 (78.2 to 100.0)88.2 (63.6 to 98.5)
Week 44 - Pre-infusion100 (79.4 to 100.0)86.7 (59.5 to 98.3)
SecondaryArea Under the sUA Concentration vs Time Curve From Day 1 to Week 24 and Day 1 to Week 48

The AUC from Day 1 to Week 24 and from Day 1 to Week 48 was calculated as time-adjusted AUC derived using the trapezoidal rule divided by the number of total days in the given period. The AUC from Day 1 to Week 48 was only calculated for participants who continued in the optional treatment period from Week 24 to Week 48.

Time frame:
Day 1 to Week 24 and Day 1 to Week 48
Reported as:
Mean · mg/dL
Area Under the sUA Concentration vs Time Curve From Day 1 to Week 24 and Day 1 to Week 48
mg/dLPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Day 1 to Week 241.4 ± 2.471.3 ± 2.24
Day 1 to Week 480.3 ± 0.780.8 ± 2.24
SecondaryPercentage of Time Participants Sustained sUA < 6 mg/dL From Day 1 to Week 24 or Day 1 to Week 48

The percentage of time that participants sustained sUA \< 6 mg/dL was derived using linear interpolation across all observed data points between Day 1 and the end of each analysis period. The percentage of time during a given period is the time that sUA \< 6 mg/dL divided by the total time from the first to the last scheduled visit in the given period.

Time frame:
Day 1 to Week 24 and Day 1 to Week 48
Reported as:
Mean · percentage of time
Percentage of Time Participants Sustained sUA < 6 mg/dL From Day 1 to Week 24 or Day 1 to Week 48
percentage of timePegloticase 16 mg + MTXPegloticase 30 mg + MTX
Day 1 to Week 2487.3 ± 25.5587.9 ± 22.76
Day 1 to Week 4898.5 ± 4.0391.4 ± 25.57
SecondaryPercentage of Participants With Anti-uricase Antibodies at Each Scheduled Visit

Pegloticase immunogenicity was assessed by incidence of anti-poly (Ethylene Glycol) (PEG) and anti-uricase immunoglobulin G (IgG) antibodies. The percentage of participants who were treatment-emergent anti-drug antibody (ADA) positive is presented below. Participants were considered treatment-emergent ADA positive if they were ADA negative at the data collection timepoint of Day 1 (Baseline) and ADA positive at one of the specified post-dose timepoints.

Time frame:
Day 1 (Baseline) and Weeks 2, 4, 8, 16, 24, 36 and 48
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-uricase Antibodies at Each Scheduled Visit
percentage of participantsPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Treatment-Emergent ADA Positive at Week 200
Treatment-Emergent ADA Positive at Week 400
Treatment-Emergent ADA Positive at Week 800
Treatment-Emergent ADA Positive at Week 1623.84.3
Treatment-Emergent ADA Positive at Week 2418.28.3
Treatment-Emergent ADA Positive at Week 36016.7
Treatment-Emergent ADA Positive at Week 486.76.7
SecondaryPercentage of Participants With Anti-PEG Antibodies at Each Scheduled Visit

Pegloticase immunogenicity was assessed by incidence of anti-PEG and anti-uricase IgG antibodies. The percentage of participants who were treatment-emergent ADA positive is presented below. Participants were considered treatment-emergent ADA positive if they were ADA negative at the data collection timepoint of Day 1 (Baseline) and ADA positive at one of the specified post-dose timepoints.

Time frame:
Day 1 (Baseline) and Weeks 2, 4, 8, 16, 24, 36 and 48
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-PEG Antibodies at Each Scheduled Visit
percentage of participantsPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Treatment-Emergent ADA Positive at Week 213.012.0
Treatment-Emergent ADA Positive at Week 424.015.4
Treatment-Emergent ADA Positive at Week 825.042.3
Treatment-Emergent ADA Positive at Week 1614.326.1
Treatment-Emergent ADA Positive at Week 2422.725.0
Treatment-Emergent ADA Positive at Week 3617.622.2
Treatment-Emergent ADA Positive at Week 486.713.3
PrimaryPercentage of Participants Who Were Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6

Responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 6. Participants meeting the sUA discontinuation criteria (pre-infusion sUA \>6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 1 Visit) were counted as non-responders.

Time frame:
Month 6 (Weeks 20, 21, 22, 23, and 24)
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
percentage of participantsPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Percentage of Participants Who Were Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 668.0 (46.5 to 85.1)73.1 (52.2 to 88.4)
PrimaryTime to First sUA ≥6 mg/dL After First Achieving sUA <6 mg/dL, From the First Pegloticase Infusion Until Week 24

The number of participants who had pre-Infusion sUA ≥ 6 mg/dL post-day 1 pegloticase infusion were included in this analysis. The date of the first pre-infusion sUA ≥ 6 mg/dL was the event date. Participants who did not have the event were censored at the date of the last collected pre-infusion sample with non-missing sUA result. Participants who never achieved sUA \< 6 mg/dL were excluded from the analysis.

Time frame:
Day 1 to Week 24
Reported as:
Mean · days
Time to First sUA ≥6 mg/dL After First Achieving sUA <6 mg/dL, From the First Pegloticase Infusion Until Week 24
daysPegloticase 16 mg + MTXPegloticase 30 mg + MTX
Time to First sUA ≥6 mg/dL After First Achieving sUA <6 mg/dL, From the First Pegloticase Infusion Until Week 2451.5 ± 39.4945.1 ± 37.19

Adverse events

Collected over MTX run-in period: Week -4 to Day 1; pegloticase + MTX treatment period: Day 1 to Week 48. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MTX Run-in0/54 (0%)0/54 (0%)21/54 (38.9%)
Pegloticase 16 mg + MTX1/25 (4%)3/25 (12%)19/25 (76%)
Pegloticase + 30 mg MTX0/26 (0%)0/26 (0%)21/26 (80.8%)
Most frequent serious events
Most frequent serious events
EventMTX Run-inPegloticase 16 mg + MTXPegloticase + 30 mg MTX
Atrial fibrillationCardiac disorders0/541/250/26
Anaphylactic reactionImmune system disorders0/541/250/26
COVID-19Infections and infestations0/541/250/26
Transient ischaemic attackNervous system disorders0/541/250/26
Most frequent other events
Most frequent other events
EventMTX Run-inPegloticase 16 mg + MTXPegloticase + 30 mg MTX
GoutMetabolism and nutrition disorders17/5418/2520/26
Infusion related reactionInjury, poisoning and procedural complications0/543/253/26
Muscle strainInjury, poisoning and procedural complications0/540/253/26
NauseaGastrointestinal disorders2/542/250/26
VomitingGastrointestinal disorders0/542/250/26
COVID-19Infections and infestations0/542/252/26
Glomerular filtration rate decreasedInvestigations1/542/250/26
White blood cell count decreasedInvestigations2/542/250/26
DizzinessNervous system disorders0/542/250/26
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/542/251/26

Baseline characteristics

Safety analysis set: All enrolled participants who received at least 1 dose of pegloticase + MTX during the trial.

Age, Continuous
Age, Continuous(years)Pegloticase 16 mg + MTXPegloticase 30 mg + MTXTotal
Mean54.2 ± 9.5655.8 ± 8.7455.0 ± 9.09
Sex: Female, Male
Sex: Female, Male(Participants)Pegloticase 16 mg + MTXPegloticase 30 mg + MTXTotal
Female213
Male232548
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pegloticase 16 mg + MTXPegloticase 30 mg + MTXTotal
Hispanic or Latino161026
Not Hispanic or Latino91625
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pegloticase 16 mg + MTXPegloticase 30 mg + MTXTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American325
White212445
More than one race000
Unknown or Not Reported000
08

Study locations

12 sites
  • Orthopedic Physicians Alaska
    Anchorage, Alaska 99508, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Glendale, Arizona 85306, United States
  • East Bay Rheumatology Medical Group, Inc.
    San Leandro, California 94578, United States
  • ProHealth Research Center
    Doral, Florida 33166, United States
  • Napa Research Center
    Pompano Beach, Florida 33064, United States
  • GCP Clinical Research
    Tampa, Florida 33064, United States
  • The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Shelby Clinical Research, LLC
    Shelby, North Carolina 28150, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • Arthritis Clinic: Western Washington Medical Group
    Bothell, Washington 98021, United States
  • Arthritis Northwest PLLC
    Spokane, Washington 99204, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in May 2023, 27 months.

Results were first posted in May 2026, 3 years after primary completion. A results delay was requested in May 2024.

Of 19 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2021
First posted
Feb 21, 2021
StartActual
Jan 26, 2021
Primary completionActual
May 18, 2023
CompletionActual
Dec 20, 2023
Results delay requested
May 6, 2024
Results first posted
May 19, 2026
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04762498
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Jan 26, 2021
Primary completion
May 18, 2023
Completion
Dec 20, 2023
Results posted
May 19, 2026
Last update
May 19, 2026

Study contacts

MD
study director · Amgen
Supra Verma, MD
study director · Horizon Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pegloticase · Methotrexate

Start the discussion